Atara Biotherapeutics, Inc. (ATRA): Nasdaq/NYSE listing notice — Atara Biotherapeutics receives Nasdaq delisting notice for market value deficiency

Atara Biotherapeutics, Inc.

Nasdaq notified Atara on April 30, 2026, that its MVLS fell below $50M for 30 consecutive business days.
Company has 180 calendar days, until October 27, 2026, to regain compliance by closing at $50M+ for 10+ consecutive days.
Stock continues trading on Nasdaq Global Select under ticker ATRA; company may consider transfer to Nasdaq Capital Market.
If not compliant by deadline, Nasdaq will provide delisting notice; Atara may appeal to a Hearings Panel.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Atara Biotherapeutics, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A), 5810(c)(3)(C)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: market value
Rules: 5450(b)(2)(A), 5810(c)(3)(C)

Exact text from the filing

April 30, 2026, Atara Biotherapeutics, Inc. (the “Company”) received a notice (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that t

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Atara Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-201397

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.